Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score

N/ANot Yet RecruitingNCT07093775

Gangnam Severance Hospital4,000 enrolled

Overview

To evaluated the prognostic significance of tumor grade in patients with node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2-negative breast cancers treated according to RS-guided strategies.

Study Type

OBSERVATIONAL

Enrollment

4,000

Conditions

Breast Cancer Tumor Grade

Interventions

Tumor grade (I or II vs. III)OTHER

We compared the prognosis according to the tumor grade stratified by 21-gene recurrence score

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with hormone receptor-positive, HER2-negative early-stage breast cancer * Patients treated between January 2011 and December 2023 * Patients with available clinicopathologic data and 21-gene Oncotype DX assay results confirmed through electronic medical records Exclusion Criteria: * Patients with breast cancer under the age of 20 * Patients diagnosed with stage IV breast cancer * Patients for whom clinicopathologic data cannot be retrieved from electronic medical records

Outcomes

Primary Outcomes

Recurrence-free interval

Time frame: through study completion, an average of 5 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.